Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02884102 | MMRF Molecular Profiling Protocol | unknown | — | 1,000 | Multiple Myeloma Research FoundationOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT04637763 | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | unknown | Phase 1 | 72 | Caribou Biosciences, Inc.INDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT06532630 | Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies | unknown | Early Phase 1 | 9 | Shanghai First Song Biotechnology Co., LTDINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06832228 | Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody (PPR) in Third or Later Line Therapy of DLBCL | unknown | N/A | 30 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06530511 | Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL | unknown | Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06539169 | FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases | unknown | — | 1,000 | xCuresINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03225417 | Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | unknown | Phase 1 / Phase 2 | 142 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT05333302 | Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma | unknown | Phase 1 | 10 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05914662 | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM(ZBR) | unknown | Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04097067 | ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma | unknown | N/A | 83 | University Hospital MuensterOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT00877214 | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas(MAINTAIN) | unknown | Phase 3 | 1,272 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06149169 | CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma | unknown | Phase 2 | 10 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04682808 | A Study of FCN-338 in Patients With Chronic CLL/SLL | unknown | Phase 1 | 99 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT04914741 | A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)(COALITION) | unknown | Phase 1 / Phase 2 | 80 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06161896 | Characterization and Clinical Impact of the Gut Microbiota in Lymphoma | unknown | — | 200 | Lars Møller PedersenOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05749549 | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | unknown | Phase 1 / Phase 2 | 191 | Shanghai Blueray Biopharma Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05190653 | Early Integration of Palliative and Supportive Care in Cellular Therapy(PALS_CT) | unknown | N/A | 152 | Alberta Health Services, CalgaryOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03244176 | Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study(AvR-CHOP) | unknown | Early Phase 1 | 28 | Austin HealthOTHER_GOV | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06508684 | Current Status of BTKi Treatment for CLL/SLL in China | unknown | — | 1,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06058858 | Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis(CMV CAR-T) | unknown | — | 250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06503094 | CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors | unknown | Phase 1 / Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06503211 | On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma | unknown | Phase 1 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06497452 | A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.(GLOFTST) | unknown | — | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06489184 | The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China | unknown | — | 490 | Peking University People's HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT01346020 | Genomic Analysis of Patients With Chronic Lymphocytic Leukemia | unknown | — | 53 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT02628405 | R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06478381 | L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma | unknown | Phase 1 | 22 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03942224 | Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma(DeRIVE) | unknown | Phase 2 | 49 | Emory UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05371392 | Polymorphism of ITGA4 Gene in Chronic Lymphocytic Leukemia | unknown | — | 80 | Sohag UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05422027 | Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | unknown | Phase 1 / Phase 2 | 42 | Xia ZhongjunOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT05422066 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 50 | Li ZhimingOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06457464 | Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients | unknown | — | 100 | Assiut UniversityOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT06445257 | A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL | unknown | N/A | 30 | Huai'an First People's HospitalOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05493800 | Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT(Capella) | unknown | Phase 2 | 60 | MitoImmune TherapeuticsINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT06424379 | BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.(BCL6-RINHL) | unknown | — | 135 | Hospices Civils de LyonOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT05189197 | A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06415708 | Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma | unknown | Phase 2 | 134 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03188172 | MUK Nine b: OPTIMUM Treatment Protocol(MUKnineb) | unknown | Phase 2 | 95 | University of LeedsOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06412068 | A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 0 | May 14, 2024 | clinicaltrials |
| NCT03292263 | ASCT With Nivolumab in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05635266 | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | unknown | — | 20,000 | Sanguine BiosciencesINDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT04499339 | A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | Wuerzburg University HospitalOTHER | 3 | Apr 25, 2024 | clinicaltrials |
| NCT06379282 | Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia(HIT-CLL) | unknown | N/A | 132 | University of SurreyOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06189833 | Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS(TAURUS) | unknown | Phase 2 | 200 | Stichting European Myeloma NetworkNETWORK | 5 | Apr 23, 2024 | clinicaltrials |
| NCT06379451 | An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma | unknown | Early Phase 1 | 9 | Changzhou No.2 People's HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06078306 | CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL). | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06084923 | Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression | unknown | — | 73 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 10, 2024 | clinicaltrials |
| NCT03213977 | R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL | unknown | Phase 3 | 475 | Fujian Medical UniversityOTHER | 1 | Mar 27, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2025source: clinicaltrials